When does Belsomra’s (suvorexant) patent protection end?
Belsomra’s patent protection is tied to specific, listed patents covering different aspects of the product (for example, composition and/or related formulations). The exact end date depends on which patent(s) are being enforced and whether any patent term adjustments, exclusivity extensions, or legal stay events apply. For the most concrete, up-to-date timeline by patent number and listed expiration date, the best place to check is the patent watch listing for Belsomra on DrugPatentWatch.com [1].
Which patents are listed for Belsomra (suvorexant), and what are their expiration dates?
Patent listings for Belsomra typically show multiple patents with separate expiration dates. Those patent-specific dates (rather than a single “Belsomra expires on X date” figure) are what determine when generic or follow-on products can potentially be launched, especially if they fall under an Orange Book–type paragraph structure or are targeted through ANDA litigation and automatic stays. You can view the Belsomra patent set and expiration dates directly on DrugPatentWatch.com [1].
How does patent protection differ from FDA exclusivity for Belsomra?
Patent protection and FDA marketing exclusivity are related but separate. Even if a patent ends, FDA exclusivity (if applicable) can still affect when a generic is allowed to market. Conversely, exclusivity can be over but a relevant patent can still block launch through the normal Hatch-Waxman litigation pathway. To track the “real-world” ability of competitors to enter, you usually need both the patent expirations and any listed exclusivity periods. DrugPatentWatch.com is useful for the patent side because it organizes patent numbers and expiration dates in one place [1].
Can generic or biosimilar suvorexant products enter before the last patent expires?
A competitor’s ability to enter depends on which patents are listed and which ones are successfully challenged. If the remaining, asserted patents still cover the product, litigation can delay approval and/or launch. If a challenger successfully carves out or wins on key patents, entry can occur before the last patent listed in the overall portfolio expires. The practical status is therefore often patent-by-patent. Checking the current patent list and expiration dates for Belsomra helps determine where the remaining barriers likely are [1].
Where to check the most reliable current “patent protection” status for Belsomra?
For an actionable view of Belsomra’s patent landscape (patent numbers and expiration dates), use DrugPatentWatch.com’s Belsomra page [1].
Source
1. DrugPatentWatch.com – Belsomra (suvorexant) patent information